Print Page    E-mail Page    RSS    E-mail Alerts 

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We ar... more >

Stock Quotemore >
C
$1.11
 Stock is Up 0.01 (0.00%)
Bellerophon (Nasdaq: BLPH)
Data as of 08/16/17 4:00 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
08/07/17
Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update
WARREN, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the second quarter ended June 30, 2017. “We continue to be encouraged with the progress of our Phase 3 clinical program in PAH, as well as Phase 2 programs in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and chronic obstructive pulmonary disease (PH-COPD).  In o... 
08/03/17
Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Company to Host Key Opinion Leader Event on PH-ILD in New York City WARREN, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced agreement with the U.S. Food and Drug Administration (FDA) on the Phase 2 study design for INOpulse® in pulmonary hypertension associated with Interstitial Lung Disease (ILD).  The Company met with the FDA in June 2017 to present positive results from its recently completed... 
05/22/17
Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference
Acute and Chronic Benefits Demonstrated with INOpulse in Patients with PH-IPF; Patients Achieved Statistically Significant Increases in Blood Vessel Volume; Consistent Improvements were Observed in Hemodynamics, 6MWD and Composite Endpoints of Oxygen Saturation and 6MWD Preliminary Results from an Ongoing Study in PH-COPD Support a Consistent Improvement in Vasodilation and Meaningful Reduction in Pulmonary Artery Pressures with 4 Weeks of INOpulse Treatment WARREN, N.J., May 22, 2017 (GLOBE... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources